NAPSRx

Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

Cerdelga™ is the only first-line oral therapy approved to treat adults with Type 1 Gaucher Disease, a rare genetic disorder that affects specific cells and organs in the body.

The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

Merck specializes in developing new therapies that treat and prevent diseases to help people in need around the world.

AstraZeneca’s Phase III program of lesinurad in combination with xanthine oxidase inhibitors produced optimistic results for gout patients. If approved, this combination therapy will add a significant boost to the company’s product pipeline.

Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

INVOKAMET™ developed by Johnson & Johnson has been approved by the FDA based on phase 3 studies which indicated the drug lowered blood sugar and is linked to significant reductions in body weight and systolic blood pressure.